Boston, MA, USA – April 22, 2024. Frontera Therapeutics is excited to announce its participation in several esteemed conferences in May 2024, where it will present groundbreaking research across multiple therapeutic areas, including ophthalmology, blood and cardiovascular diseases. The conferences are the 2024 Retinal Cell and Gene Therapy Innovation Summit, the 2024 American Ophthalmology Congress, and the 27th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT).
Since its inception, Frontera Therapeutics has established a R&D center in Boston, USA, complemented by clinical operations and GMP manufacturing facilities in Shanghai and Suzhou, China. The company’s recombinant adeno-associated virus (AAV) expression system based on insect cell Sf9 has achieved 500L scale-up capabilities, with the potential to reach up to 2000 L. Moreover, Frontera has developed an innovative purification process that improves product safety standards, underscoring its commitment to delivering high-quality, cost-effective AAV gene therapy drugs to patients worldwide.
Dr. Xinyan Li, Chief Executive Officer of Frontera Therapeutics, expressed confidence in the company’s progress, stating, “Our gene therapy drugs, potentially ‘First in Class’ and ‘Best-in-Class’, have made significant strides in clinical development. Our validated AAV construction, screening, and scalable platform technology reaffirm our commitment to meeting diverse clinical needs. With our established large-scale GMP production capabilities, we are well-equipped to address the requirements of patients across different therapeutic indications. Frontera’s rich R&D pipeline, which encompasses rare ophthalmic diseases, chronic illnesses, blood disorders, and cardiovascular conditions, offers significant market potential for drug development. We look forward to engaging with industry peers at the upcoming conferences to explore new opportunities for gene therapy technology development and cooperation.”
2024 Innovation Summit on Retinal Cells and Gene Therapy
Date: 03-May
Location: Seattle, USA
Preliminary clinical safety and efficacy data of FT-002 from Frontera Therapeutics will be presented orally at the “2024 Innovation Summit on Retinal Cells and Gene Therapy”, with the following reporting topic: Preliminary safety and efficacy results from an open-label, dose-escalation pilot gene therapy study of FT-002 in subjects with RPGR gene mutation associated X-linked Retinitis Pigmentosa (XLRP)
The Association for Research in Vision and Ophthalmology (ARVO) 2024
Date: May 4-9
Location: Seattle, USA
The poster displayed by Frontera Therapeutics at the “The Association for Research in Vision and Ophthalmology ARVO 2024” is the following: Phase I study evaluating the safety, tolerability and preliminary efficacy of FT-001 gene therapy for RPE65 associated retinal dystrophy ( Poster 5308 – #B0245)
27th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT)
Date: May 7-11
SETTING: Baltimore, Maryland, USA Frontera Therapeutics will present posters on 7 topics covering clinical, preclinical, and pharmaceutical development at the “2024 American Society for Gene and Cell Therapy (ASGCT) Annual Meeting”, and the specific topics are the following.
| Time | Abstract content | Presentation type |
| May 8, 2024， 12:00 PM | Preliminary safety and efficacy results from an open-label, dose-escalation pilot gene therapy study of FT-002 in subjects with RPGR gene mutation associated X-linked Retinitis Pigmentosa (XLRP) | Poster NO. 918 |
| May 8, 2024，12:00 PM | Efficacy and Safety of a Novel RPGR OFR15 Gene Therapy (FT-002) for the Treatment of RPGR-Associated XLRP | Poster NO. 657 |
| May 9, 2024，12:00 PM | Development of an AAV Gene Therapy Vector FT-004 for Hemophilia B | Poster NO. 1088 |
| May 8, 2024，12:00 PM | Developing an AAV-based Gene Therapy for MYBPC3 Mutation-Associated Hypertrophic Cardiomyopathy | Poster NO. 610 |
| May 10, 2024，12:00 PM | AAV KP1 Efficiently Transduces Human Cell Lines in vitro and Mouse Liver but not Non-Human Primate Liver after Intravenous Injection | Poster NO. 1464 |
| May 8, 2024，12:00 PM | Development and Characterization of a Rhabdovirus-Free Clonal Sf9 Cell Line for Enhanced Safety and Enhanced AAV Production in the Baculovirus Expression Vector System | Poster NO. 566 |
| May 10, 2024，12:00 PM | Addressing Downstream Purification Challenges: Solving AAV2 Aggregation Issue and Developing Innovative Approaches for Empty Capsid Removal | Poster NO. 1514 |